Oral Steroid Treatment for Chronic Rhinosinusitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01255683|
Recruitment Status : Withdrawn (Lack of proposed funding.)
First Posted : December 7, 2010
Last Update Posted : April 22, 2015
|Condition or disease||Intervention/treatment|
|Chronic Rhinosinusitis||Drug: oral corticosteroid taper|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Single-arm Clinical Evaluation of Oral Steroid Treatment for Chronic Rhinosinusitis|
|Study Start Date :||December 2010|
|Estimated Primary Completion Date :||November 2011|
|Estimated Study Completion Date :||November 2011|
Drug: oral corticosteroid taper
This is an observational study in which patients self-select oral steroid treatment for symptoms of CRS. Drug treatments are NOT assigned in this investigation.
- Health-related quality-of-life [ Time Frame: Change from baseline to 6 months ]The two main outcome measures to evaluate changes in QoL include the Sinonasal Outcome Test-22 (SNOT-22) and Nasal Obstruction Scoring Evaluation (NOSE) instruments. The SNOT-22 is a validated, 22-item outcome measure applicable to both sinonasal conditions and surgical treatments (score range: 0-110). Lower total scores on the SNOT-22 imply better QoL. The SNOT-22 will be administered by the Study Coordinator to study participants at baseline, as well as 2 week, 1 month, 3 month, and 6 month follow-up appointments.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01255683
|United States, Oregon|
|Oregon Health & Science University|
|Portland, Oregon, United States, 97239|